unknown
Stage
About
Digistain develops a clinical diagnostic technology that uses infrared spectroscopy to analyze tissue chemistry for pathology, enabling objective assessment of cancer tissue and prediction of treatment response. Their solutions are intended for use by hospitals and pathology laboratories to support cancer diagnosis and therapy decision-making.
Explore Digistain's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.